Veranex

Many workshops end with a longer list of open questions. Veranex facilitates working sessions that end with decisions: a clear pathway, defined evidence needs, and owners on your team who can move them forward.

FDA clearance is one milestone. Payer coverage is another, and it often depends on evidence a pivotal study wasn't designed to produce. In one short working session, Veranex's clinical strategy and market access team will map your top evidence priorities and a path to align them.

Clinical, regulatory, and reimbursement evidence are often planned separately, and the gaps show up later as extra studies, delays, or coverage hurdles. Veranex's Integrated Evidence Planning aligns all three from day one, so one study strategy supports approval, clinician adoption, and payer coverage.

The costliest design mistakes happen before anything gets built. Veranex design sprints combine user research, clinical workflow insight, and regulatory considerations in one focused engagement, so your team commits to the right problem before it commits budget to a build.

Four decision areas. 16 questions. One score that tells you whether your preclinical CRO is built for regulatory compliance or clinical translation. Download the framework and rate your next candidate from "strong" to "not recommended" before the contract is signed.

Taking a device to first-in-human? Your preclinical partner shapes more than your GLP package. They influence regulatory readiness, investigator confidence, and how fast sites adopt. Download the guide for 16 questions to bring to your next CRO conversation.